Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Monday, October 28, 2024
The bispecific antibody ivonescimab combined with chemotherapy may improve clinical outcomes for patients with locally advanced unresectable or metastatic triple-negative breast cancer, according to Xiaojia Wang, MD, PhD, of Zhejiang Cancer Hospital, Hangzhou, China, and colleagues. Ivonescimab targets both PD-1 and VEGF, and when combined with chemotherapy, it yielded antitumor activity in these patients, including a disease control rate of 100%. The findings of this open-label, multicenter phase II study were presented at the European Society of Medical Oncology (ESMO) Congress 2024 (Abstract 347MO).
“Locally advanced unresectable or metastatic triple-negative breast cancer is highly aggressive and has a poor prognosis. Ivonescimab, a tetrameric bispecific antibody targeting PD-1 and VEGF, has the potential to produce complementary and synergistic antitumor effects through both pathways via cooperative binding,” stated the investigators.
Patients with locally advanced unresectable or metastatic triple-negative breast cancer received ivonescimab (20 mg/kg every 2 weeks) and paclitaxel (90 mg/m2) or nab-paclitaxel (100 mg/m2) on days 1, 8, and 15 of each 4-week treatment cycle (n = 30). The median age of patients was 54, 80% had a PD-L1 combined positive score (CPS) of < 10, and 60% had previously received taxane-based neoadjuvant therapy.
At the median follow-up of 7.2 months, the objective response rate in 29 evaluable patients was 72.4%, with a disease control rate of 100%. The objective response rates for patients with a PD-L1 CPS ≥ 10 and < 10 were 83.3% and 69.6%, respectively. Progression-free survival rate at 6 months was 68.4%, although median progression-free survival and overall survival data are not yet mature.
A total of 14 of 30 patients (46.7%) experienced at least one grade ≥ 3 treatment-related adverse event. No treatment-related adverse events led to treatment discontinuation or death.
Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.
JNCCN Spotlights
Resources
For your Patients
